A Rare Case of Small Cell Carcinoma of the Urinary Bladder

Hossain, Samia; Keshava, Vinay Edlukudige; Minupuri, Arun; Thirumaran, Rajesh; Choi, Eugene

doi:10.7759/cureus.8609

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their findings are inconsistent with our experience in this case. Comparable to our findings, Hossain et al reported that SCBC with muscle metastasis treated with a similar therapy achieved at least four months of disease control [ 5 ]. However, only a few cases have reported similar findings.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab

Kamitani

Ando²,

Hanai³

et al. 2022

BMC Urol

View full text Add to dashboard Cite

Background Small cell bladder carcinoma (SCBC) is a rare and aggressive malignant tumor with no established treatment guidelines. Its treatment algorithm has been based on the small cell lung cancer (SCLC) guidelines. Metastatic SCBC has poor prognosis (even when treated with platinum-based chemotherapy, which is usually used for extensive-disease SCLC). Case presentation Herein, we report a case of a 71-year-old man with SCBC who underwent radical cystectomy and received adjuvant chemotherapy with gemcitabine and cisplatin. However, recurrent tumors were found 6 months postoperatively. The patient was then treated with carboplatin, etoposide, and atezolizumab and achieved complete response. He continues receiving maintenance therapy with atezolizumab monotherapy without any evidence of recurrence over the 12 months follow up. Conclusion To our knowledge, this is the first case of metastatic SCBC where carboplatin, etoposide, and atezolizumab achieved long-term complete response.

show abstract

Section: Discussionsupporting

confidence: 82%

“…Recently, combining chemotherapy with immunotherapy has attracted attention as a treatment option for extensive-disease SCLC [ 4 ]. However, few reports have described its efficacy for SCBC [ 5 ]. We report the first case of metastatic SCBC where carboplatin, etoposide, and atezolizumab achieved long-term complete response.…”

Section: Introductionmentioning

confidence: 99%